LiDCO Group Plc
11 August 2005


For immediate release                                           11 August 2005


                                LiDCO Group PLC
                                (the "Company")

   US$2 million financing agreed for sales expansion following additional
                           regulatory approvals

LiDCO Group Plc, the UK-based AIM-traded cardiovascular monitoring company is
pleased to announce that it has entered into a US$2 million three year secured
revolving convertible loan agreement on 10th August 2005 with Laurus Master
Fund, Ltd. ("Laurus"). Laurus is a US based provider of finance to small cap
growth companies. Interest is payable on any outstanding amount at a rate of
1.5% above the Wall Street Journal prime rate. Any amount outstanding under this
facility may be converted into LiDCO ordinary shares, at either the Company's or
Laurus' discretion. The conversion price is 24p (the "Fixed Conversion Price").
If LiDCO exercises its conversion right, the price will be set at the lower of
the Fixed Conversion Price or 85% of the average closing price for the 10 days
immediately prior.

Having achieved international regulatory approvals and while establishing a
global distribution network, the funds will assist LiDCO as it seeks to grow its
sales worldwide.

Under the terms of the agreement, Laurus is generally restricted from holding
more than 3% of the Company's issued share capital at any one time on any
conversion of the loan. In association with the facility the Company has also
today granted options to Laurus and its agent to subscribe for 1,123,596 new
ordinary shares in the Company at 30p per share, exercisable at any time until
10th August 2010.

Dr Terry O'Brien CEO LiDCO Group Plc stated: "The Laurus facility provides us
with financial flexibility that allows us to underpin our working capital as we
grow sales of LiDCO's minimally invasive cardiovascular monitoring products. At
the half year point the Board is pleased to report that trading is broadly in
line with expectations."

For further information please contact:


LiDCO Group Plc
Terry O'Brien (CEO) terry@lidco.com                                020 7749 1500
Hugh McGarel-Groves (FD) hugh.mcgarel-groves@lidco.com

Buchanan Communications
Tim Anderson, Mary-Jane Johnson, James Strong                      020 7466 5000

Panmure Gordon
Grant Harrison, Aubrey Powell, Marcus Jackson                      020 7459 3600



Notes to Editors

About Laurus Capital Management LLC

Laurus is a US based financial institution that provides finance to small and
micro cap growth companies. Their flexible financing solutions are designed to
help build cash reserves and enable management to focus on operations and
strategic growth opportunities.

About LiDCO Plc

LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier of
minimally invasive, computer-based hemodynamic monitoring equipment and
disposables used primarily for the management of critical care and
cardiovascular risk hospital patients. Use of LiDCO's technology has been shown
to significantly reduce the complications (particularly infections) and costs
associated with major surgery.  The technology was invented in the Department of
Applied Physiology based at St Thomas' Hospital, London where the Company
maintains a research base.

The Company's manufacturing facility is in Hoxton, London and its current
products are:

• LiDCOplus and PulseCO monitors: computer-based platforms for displaying a
  range of real-time, continuous hemodynamic parameters including cardiac 
  output, oxygen delivery and fluid volume;

• LiDCO disposables: used in conjunction with the LiDCOplus Monitor to
  accurately determine cardiac output in a minimally-invasive manner.


Distribution Network:

The Company has now achieved registration of its products in 13 markets in
Europe, the USA, Brazil and Japan.  It sells direct to the NHS in the UK, and
through a worldwide network of specialty critical care distributors.

Background to the recently published clinical trial: Better than standard care -
(EGDT) improves outcome in high risk surgery patients:

The results of a major trial at St George's Hospital, London using LiDCO's
minimally invasive monitoring technology were presented during the 25th
International Symposium on Intensive Care and Emergency Medicine in Brussels
(21st to 25th March). The results have revealed the following:

a) Savings in the cost of treating patients amounting to an average of £4,000
   per patient.  Extrapolated nationally, this would equate to a saving of £500
   million per annum for the NHS

b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62
   patients, an average of more than 10 bed days per patient

c) The savings in cost and hospital days were associated with a significant
   reduction in medical complications (particularly infections - which were 
   halved) through the use of LiDCO's minimally invasive technology to improve 
   tissue oxygen levels following surgery.


                      This information is provided by RNS
            The company news service from the London Stock Exchange